By Budi Oetomo Narendra 
Aging, an inevitable biological process, manifests at vastly different rates across individuals, yet its universal impact eventually touches every aspect of human physiology. Breakthrough research from Stanford Medicine, conducted across both mouse models and human cells, has illuminated a critical vulnerability within the immune system that may fundamentally explain this variability and the broader decline associated with advancing years. The findings point to a specific failure in how immune cells clear cellular debris, a process central to maintaining youthful organ function.
The Immune System’s Unsung Custodians: Macrophages and the Aging Dilemma
At the heart of this discovery lies the impaired function of tissue-resident macrophages. These specialized immune cells are permanent residents within organs, where they perform a myriad of vital tasks, including pathogen surveillance, immune response coordination, and tissue repair. Crucially, they act as the body’s cellular "garbage collectors," tasked with disposing of dead, damaged, and senescent cells—a function found to deteriorate significantly with age. This decline, the research suggests, is not merely a symptom of aging but a significant contributor to systemic age-related deterioration.
The Stanford team’s investigation revealed that as these tissue-resident macrophages age, their capacity to efficiently clear another prevalent class of immune cells, known as neutrophils, diminishes. This failure in cellular disposal appears to fuel a cascade of aging processes throughout the body. In a compelling demonstration of this mechanism, scientists found that by merely blocking a single receptor on these macrophages, numerous organs in mice retained remarkably youthful characteristics. The rejuvenating effects were observed across a wide spectrum of vital organs, including the brain, heart, skeletal muscle, liver, spleen, bone marrow, kidney, and colon, underscoring the systemic reach of this immune pathway.
This specific receptor normally responds to a hormone, prostaglandin E2 (PGE2), which plays a significant role in inflammation and pain in both mice and humans. Disabling this receptor, specifically within tissue-resident macrophages, provided remarkable protection to mice against a host of problems commonly associated with chronic inflammation and aging. These benefits included a reduction in frailty, decreased accumulation of excess fat, and mitigation of cardiac issues. Furthermore, cognitive decline, a debilitating hallmark of aging, was substantially reduced. Dr. Katrin Andreasson, the Edward F. and Irene Thiel Pimley Professor in Neurology and Neurological Sciences and senior author of the study, remarked, "We’ve been trying to figure out why we age. Now we know at least one big reason for it."
The comprehensive findings of this study were meticulously detailed in a paper published in the prestigious journal Science. Dr. Andreasson spearheaded the research as senior author, with Dr. Jessy Tan, an instructor in neurology, serving as the lead author. The research not only provides profound new insights into the pervasive role of chronic, body-wide inflammation in aging and its associated health burdens but also illuminates a promising potential drug strategy. Such a therapeutic approach could potentially slow age-related organ deterioration and, more significantly, extend the number of years individuals remain healthy, a concept known as "healthspan."
The Unseen Battle: How the Immune System Manages Cellular Lifecycles
To fully appreciate the significance of these findings, it is essential to understand the dynamic and often overlooked process by which the immune system continually clears aging cells. Neutrophils, the most abundant type of white blood cells, are the immune system’s frontline responders. Produced in the bone marrow, these cells circulate in the bloodstream, constantly patrolling for bacterial, viral, and fungal threats. Their role is critical: upon encountering pathogens, neutrophils can release toxic substances and even self-destruct, spilling their biological contents to form web-like traps around invading microbes.
However, neutrophils are inherently short-lived. Their typical lifespan ranges from a mere 12 to 24 hours. After their brief but intense service, approximately 90% of circulating neutrophils make their way to the liver, spleen, and bone marrow, where other immune cells are responsible for their removal. This disposal mechanism is not merely about maintaining order; it becomes increasingly vital as the body ages. In older animals, a significant proportion of neutrophils that never even encounter a pathogen rapidly enter a state of senescence. Senescent cells are dysfunctional and can release a cocktail of harmful chemicals that damage nearby healthy cells and actively promote chronic inflammation—a phenomenon increasingly recognized as "inflammaging."
The problem compounds with age: not only do neutrophil numbers generally increase, but a growing proportion of these cells become senescent. "Senescent neutrophils are killing our tissues," Dr. Andreasson stated, emphasizing the destructive potential of these accumulating dysfunctional cells. "Clearance of these cells is essential for preventing chronic inflammation." This highlights a critical, often overlooked aspect of immune health: the efficiency of cellular turnover is as important as the initial immune response.
Macrophages: The Body’s Elite Sanitation Crew
Macrophages are the primary architects of this crucial cellular cleanup. These remarkably versatile immune cells are fundamental to maintaining homeostasis. Beyond fighting pathogens and coordinating immune responses, they also release growth factors vital for damaged tissue repair. Their role as "garbage collectors" is paramount, constantly engulfing and digesting dead, damaged, and dysfunctional cells. Dr. Andreasson aptly describes them as "the body’s garbage collection crew. A lot of that garbage is defunct cells."
A substantial portion of this cellular waste consists of neutrophils. The sheer scale of this daily task is staggering: approximately 100 billion neutrophils need to be cleared every day. This continuous high-volume disposal operation is a testament to the immune system’s efficiency in youth.
Among the various types of macrophages, tissue-resident macrophages are particularly noteworthy. These cells are unusually long-lived, establishing themselves in organs during fetal development and remaining in those specific locations throughout an individual’s life. Once settled, they adapt to perform specialized tasks unique to their respective organs. One of their most critical responsibilities is the engulfment of senescent cells, with neutrophils identified as particularly significant targets. Even neutrophils that haven’t fully entered senescence but have reached the end of their operational lifespan signal their readiness for disposal, putting out "kill me now" flags on their cell surfaces, making them fair game for macrophage clearance.
The core challenge identified by the Stanford team is that tissue-resident macrophages themselves deteriorate with age. Building upon previous research, Dr. Andreasson and her colleagues reported in a 2021 Nature study that these long-lived immune cells become increasingly vulnerable to inflammation as animals grow older. This vulnerability can, in turn, cause them to contribute to the very inflammation they are supposed to combat. The efficiency of the "garbage collection crew" is compromised, leading to a backlog of harmful cellular waste.
An Inflammatory Signal Amplified by Age: The EP2 Receptor Pathway
A key component of this age-related decline involves prostaglandins, a class of hormones produced by immune cells. Specifically, one of the five types, prostaglandin E2 (PGE2), exerts diverse effects on cells, depending on the specific receptors present on their surfaces. A particular receptor for PGE2, known as EP2, is a strong promoter of inflammation. Significantly, tissue-resident macrophages contain high concentrations of EP2 receptors.
PGE2 production naturally increases in response to infection, injury, and exposure to toxic substances, including compounds generated during the aging process. The researchers’ earlier work had already established that PGE2 levels rise substantially over time. Concurrently, tissue-resident macrophages develop even higher concentrations of EP2. These two age-related changes converge to create a deleterious feedback loop: increasing PGE2 activity repeatedly stimulates the EP2 receptors on tissue-resident macrophages. The new study conclusively demonstrated that this chronic stimulation severely impairs the macrophages’ ability to engulf and dispose of neutrophils.
The consequence is a detrimental accumulation of senescent neutrophils in the bloodstream and various tissues, further exacerbating chronic inflammation and tissue damage. Prior research from Dr. Andreasson’s group also revealed that the energy metabolism of tissue-resident macrophages gradually deteriorates with age, a factor that profoundly impacts their performance. "Once that starts, there’s a steady decline in a macrophage’s performance," she noted. The current study strongly implicates the EP2 receptor as a critical orchestrator of this decline. "We’ve shown that when tissue-resident macrophages don’t have EP2 on their surfaces anymore or when that receptor is plugged up by a drug, this decline doesn’t happen," Dr. Andreasson affirmed, highlighting a potential therapeutic target.
Targeting EP2: Protecting Multiple Organs and Reversing Age-Related Decline
To rigorously investigate the EP2 receptor’s precise role, Dr. Andreasson’s laboratory engineered a sophisticated mouse model. These mice were designed such that their EP2 gene could be selectively deleted at a predetermined time, specifically within their tissue-resident macrophages. The results were compelling: removing EP2 successfully restored the macrophages’ ability to efficiently dispose of neutrophils, effectively reversing the disruptive effects caused by elevated PGE2 activity.
The researchers conducted a comparative study involving younger normal mice (aged 6 to 8 months, roughly equivalent to late adolescence or early adulthood in humans), older normal mice (aged 23 to 25 months, comparable to humans in their 60s or 70s), and a third group of nearly identical older mice whose EP2 gene had been deleted when they were 4 to 6 months old (their "teenage" years). This experimental design allowed for a direct assessment of EP2’s impact on the aging process.
Analysis of blood proteins revealed a dramatic effect. In normal older mice, 71 blood proteins showed significantly altered levels indicative of aging. Remarkably, in the older mice whose tissue-resident macrophages lacked EP2, 59 of these proteins remained at youthful levels. Many of these proteins originated from the liver, an organ rich in tissue-resident macrophages and a major metabolic hub. Dr. Andreasson explained, "The liver is one of the body’s most tissue-resident-macrophage-enriched organs and a major contributor to aging-related changes in blood chemistry. It’s the central organ determining the body’s metabolic rate."
The accumulation of senescent neutrophils was evident in the liver, spleen, and bone marrow of normal old mice, with smaller increases observed in other examined organs. In stark contrast, older mice whose tissue-resident macrophages lacked EP2 maintained the lower neutrophil levels typically observed in younger animals, underscoring the protective effect of EP2 deletion.
Beyond molecular markers, the physical manifestations were equally striking. The EP2-deleted mice appeared younger, leaner, and exhibited greater physical fitness than their age-matched control counterparts. They displayed less visceral fat, more muscle mass, and their performance on tests assessing the function of various organs mirrored that of young mice.
Enhancing Memory, Strength, and Reducing Systemic Inflammation
The benefits extended beyond metabolic and physical markers. Removing EP2 from tissue-resident macrophages significantly reduced inflammation not only in the blood but also in critical organs such as the liver, colon, heart, kidney, and the hippocampus—a brain region intrinsically linked to memory and navigation abilities.
Furthermore, older mice without EP2 performed comparably to younger animals on tests measuring speed, balance, and forelimb grip strength, indicating a preservation of motor function and overall vitality. Their cognitive abilities also remained robust. They navigated mazes and remembered previously encountered objects almost as effectively as younger mice, substantially outperforming similarly aged mice whose EP2 receptors remained functionally active. These results suggest a profound protective effect against age-related cognitive decline, a major public health concern.
The Quest for a Targeted Therapeutic: Blocking EP2
While the findings are highly promising, a selective drug that can shut down EP2 activity without interfering with other crucial biological pathways is not yet approved. Currently, several medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin, reduce PGE2 production. Dr. Andreasson pointed out that this is the mechanism by which NSAIDs alleviate pain, fever, swelling, and redness—the classic "four horsemen" of inflammation. However, these broad-spectrum medications also interfere with other prostaglandins that perform essential functions. Moreover, PGE2 itself can exert beneficial effects when interacting with receptors other than EP2.
Therefore, the scientific community’s focus is on developing a drug that specifically targets the EP2 receptor, thereby selectively blocking the harmful inflammatory response without causing undesirable collateral effects. To test the feasibility of this targeted approach, the scientists administered an experimental drug that inhibits EP2 to otherwise normal 22-month-old mice for a period of two months. The treatment yielded encouraging results: both total neutrophil levels and the number of senescent neutrophils in these older mice moved closer to youthful levels. In vitro experiments with cell cultures further confirmed that while aging diminished the ability of tissue-resident macrophages to engulf and digest worn-out neutrophils, the EP2-blocking drug significantly restored this critical function.
Translational Insights: Similar Patterns in Human Liver Cells
To bridge the gap between animal models and human biology, the researchers meticulously examined a vast database containing information about different cell types in young, old, and diseased human livers. The analysis revealed striking parallels to the observations in mice. Older human livers exhibited increased neutrophil accumulation, a greater incidence of neutrophil senescence, declining tissue-resident macrophage function, and elevated EP2 activity. These detrimental changes were even more pronounced in diseased livers, underscoring the clinical relevance of the findings. Dr. Andreasson highlighted that this marked the first time these specific age-related changes had been observed in human cells, providing crucial validation for the study’s translational potential.
Implications and Future Directions for Geroscience
The ability to improve the body’s efficiency in removing aging neutrophils could herald significant therapeutic benefits, potentially transforming the landscape of age-related disease prevention and treatment. The findings align with the broader field of geroscience, which seeks to understand the fundamental mechanisms of aging to extend healthy lifespan. Other strategies in geroscience, such as the development of senolytics (drugs that selectively kill senescent cells), share a common goal of reducing the burden of cellular senescence. The Stanford study offers a novel, distinct approach by focusing on enhancing the clearance mechanism rather than directly targeting senescent cells for destruction.
The next critical step, according to Dr. Andreasson, is the development of a safe and highly selective drug that blocks EP2 without interfering with earlier processes like PGE2 production, which can have beneficial roles. Such a drug could potentially offer a new strategy to combat age-related chronic inflammation, protect organ function, and ultimately extend the healthspan of individuals, allowing people to live healthier, more vibrant lives into old age. This research represents a significant leap forward in understanding the complex interplay between the immune system and the aging process, offering a beacon of hope for future anti-aging interventions.
A researcher from the University of Munster in Germany also contributed to this groundbreaking study. The research received substantial financial support from the National Institutes of Health (grants 1RF1AG080742, 1RF1AG070839, and P30AG066515), the American Heart Association, the Phil and Penny Knight Initiative for Brain Resilience (at the Wu Tsai Neurosciences Institute), Stanford University, the Arc Institute, and the Chan-Zuckerberg Biohub. Part of the intricate experimental work was conducted at the Neurosciences Preclinical Imaging Community Laboratory at the Wu Tsai Neurosciences Institute.
